Will the Selecta Biosciences Restructuring Pay Off?

Health and Healthcare

Published: January 4, 2019 11:35 am

Last Updated: January 11, 2020 12:58 pm

Selecta Biosciences Inc. (NASDAQ: SELB) shares pushed higher on Friday after the company provided an update on its new streamlined structure under its new president and chief executive officer.

In its midstage gout study, Selecta showed interim data that reduced total urate burden and lowered flare rates and severity. This was all observed in the Phase 2 clinical trial, and SEL-212 continued to be generally well tolerated.

Back in September, Selecta announced a collaboration with the European consortium, CureCN, for an ImmTOR+AAV gene therapy combination product candidate in Crigler-Najjar syndrome.

Also effective, December 1, 2018, Carsten Brunn, Ph.D., assumed the role of president and CEO of Selecta, following his previous position as president of Pharmaceuticals for the Americas and member of the Global Pharmaceutical Executive Committee at Bayer.

Overall, the company is restructuring to reduce the current workforce by 36% as of January 3, 2019. This reduction, coupled with a reprioritization of the company’s pipeline programs, is projected to reduce the yearly cash burn by 19% going forward.

Brunn commented:

We believe 2019 will be a transformative year for Selecta with key milestones anticipated for both our chronic refractory gout and gene therapy programs. We intend to focus on executing our strategic priorities, advancing our ImmTOR platform, and growing our strategic partnerships. With this renewed focus, we plan to deprioritize our oncology pipeline and undergo a restructuring to better align with our new priorities. The restructuring was a difficult decision and I want to personally thank all those who are affected for all their contributions to Selecta,

Shares of Selecta were last seen up about 21% at $2.78, in a 52-week range of $2.28 to $16.54. The consensus analyst price target is $26.33.

ALSO READ: Bull/Bear Outlook for 2019: How All 30 Dow Stocks Could Take the Market Up to 28,000

The Average American Has No Idea How Much Money You Can Make Today ^(Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

¹https://www.fdic.gov/national-rates-and-rate-caps